Abstracts tagged "lymphocytes and systemic sclerosis"

Abstract Number: 1122 • 2018 ACR/ARHP Annual Meeting
Lymphocyte Immunophenotypes at Randomization on the Scleroderma: Cyclophosphamide or Transplantation Trial: Comparison of Treatment Naïve and DMARD Treated Participants with Healthy Controls
Ankoor Shah¹, Jan Storek², Rob Woolson³, Lynette Keyes-Elstein⁴, Paul Wallace⁵, Maureen D. Mayes⁶, Leslie Crofford⁷, Daniel E. Furst⁸, Ellen Goldmuntz⁹, Richard Nash¹⁰, Peter McSweeney¹⁰ and Keith Sullivan¹¹, ¹Medicine, Duke University Medical Center, Durham, NC, ²University of Calgary, Calgary, AB, Canada, ³Rho Inc, Chapel Hill, NC, ⁴Clinical Statistics, Rho Federal Systems, Inc., Chapel Hill, NC, ⁵Roswell Park Cancer Institute, Buffalo, NY, ⁶Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁷Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ⁸Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁹NIH, Bethesda, MD, ¹⁰Colorado Blood Cancer Institute, Denver, CO, ¹¹Duke University Medical Center, Durham, NC
Background/Purpose: The Scleroderma:Cyclophosphamide or Transplantation Trial (SCOT) study compared stem cell transplant to monthly cyclophosphamide (CYC) in patients with scleroderma (SSc). We studied baseline lymphocyte…
Abstract Number: 2068 • 2016 ACR/ARHP Annual Meeting
Type 2 Innate Lymphoid Cells – Cellular Source of Profibrotic Mediators Rapidly and Persistently Recruited in Experimental Fibrosis and Systemic Sclerosis
Stefanie Weber¹, Thomas Wohlfahrt¹, Simon Rauber¹, Markus Luber¹, Matthias Englbrecht², Clara Dees³, Christian Beyer⁴, Oliver Distler⁵, Georg Schett³, Joerg HW Distler³ and Andreas Ramming⁴, ¹Department of Internal Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3, Rheumatology & Clinical Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁴Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: We aimed to profile ILC2s in fibrotic tissues and to evaluate the functional impact of IC2s in the pathogenesis of systemic sclerosis (SSc). Methods:…
Abstract Number: 773 • 2014 ACR/ARHP Annual Meeting
Functional Autoantibodies from Patients with Systemic Sclerosis Reactive to Angiotensin II Type 1and Endothelin-1 Type a Receptor Induce Inflammatory Lymphocyte Infiltration into Lungs of Mice
Angela Kill¹, Clement Braesch¹, Anja Kühl², Jeannine Guenther³, Mike O. Becker⁴, Gerd Burmester⁵, Thomas Walther⁶ and Gabriela Riemekasten⁷, ¹Rheumatology and clinical Immunology, Charité University Hospital, German Rheumatology Research Center, a Leibniz Institute, Berlin, Germany, ²Department of Internal Medicine, Charité University Hospital, Berlin, Germany, ³Rheumatology and Clinical Immunology, Charité University Hospital, German Rheumatology Research Center, a Leibniz Institute, Berlin, Germany, ⁴Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany, ⁵Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ⁶Pharmacology & Therapeutics, University College Cork, Cork, Ireland, ⁷Charité University Hospital and German Rheumatism Research Centre, a Leibniz Institute, Berlin, Germany
Background/Purpose Functional autoantibodies reactive to the angiotensin II type 1 receptor (AT1R) and endothelin 1 type A receptor (ETAR) were found in elevated levels in…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.